Innovation Pharmaceuticals Inc. IPIX
0.00 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
0.0007 Day range 0.012
0.0001 52-week range 0.05
- YTD
- -80.00%
- 1 year
- -71.43%
News
businesswire.com Innovation X Advisors Participates in Shield AI's $1.5 Billion Series G Financing NEW YORK--(BUSINESS WIRE)--Today, late-stage venture capital firm Innovation X Advisors LLC (“Innovation X”) announced its participation in the $1.5 billion Series G financing of Shield AI, Inc.…
prnewswire.com AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination BOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced…
https://www.businesswire.com INVNT™ Announced as Sponsor and Co-Producer of Discovery Stage at SXSW Sydney® 2024 SYDNEY--(BUSINESS WIRE)--INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at…
globenewswire.com Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024 WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT…
globenewswire.com Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium WAKEFIELD, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral research…
globenewswire.com Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19 WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the…
globenewswire.com Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19 WAKEFIELD, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that enrollment has surpassed…
globenewswire.com Innovation Pharma's Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation WAKEFIELD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the…
globenewswire.com Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology's Annual Meeting WAKEFIELD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral data related…
globenewswire.com Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients WAKEFIELD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that an independent Data…
globenewswire.com Innovation Pharma's COVID-19 Drug Candidate Brilacidin Ranked in Top Three Percent of Compounds Predicted to Be Most Effective Against SARS-CoV-2 WAKEFIELD, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine…
globenewswire.com Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma's Phase 2 Clinical Trial of Brilacidin for COVID-19 WAKEFIELD, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports that eight sites are now…
globenewswire.com Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for Treating COVID-19 Scheduled to Begin Next Week WAKEFIELD, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that the Company's Phase 2…
globenewswire.com Innovation Pharmaceuticals' Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month
benzinga.com Stocks That Hit 52-Week Lows On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Tuesday